Gestational breast cancer: distinctive molecular and clinico-epidemiological features

Gestational breast cancer (GBC), defined as breast cancer (BC) diagnosed during pregnancy or the first-year post-partum, accounts for 6-15% of BC cases in women aged 20-44 years. GBC has worse prognosis than non-GBC, but reasons behind are not clear. The GEICAM/2012-03 Study (Molecular Characterization of Gestational Breast Cancer) is a multicenter prospective/retrospective observational registry of patients diagnosed with GBC. From November 2014 to June 2015 seventy patients diagnosed with GBC were included in the study, 30 diagnosed during pregnancy and 40 after delivery. Our current study was aimed to explore differences in epidemiological, clinico-pathological and gene expression features of GBC tumors, from the GEICAM/2012-03 Study, compared to non-GBC tumors from patients of similar age (< 43 years) from six different GEICAM studies, used as non- GBC control population. As per the main objective, the study found multiple differences showing GBC tumors as a different biological entity. GBC showed a more aggressive biology, with higher Ki67 levels, higher incidence of breast and/or ovarian cancer family history, and germline deleterious BRCA1/2 mutations, and are enriched in basal-like intrinsic subtype. GBC patients showed a lower number of tumor infiltrating lymphocytes, while specific genetic signatures highlight differences in GBC´s distinctive transcriptome. Our study shows that GBC is potentially a clinically and molecularly different entity, with specific epidemiological, clinical, and histological features, as well as a distinctive altered immune state and genetic signature. Nevertheless, further studies are needed to better understand the biology of GBC and to identify new targets against which develop new, more effective, targeted therapies.

Authors

Institutions

Publication Details

Journal
Journal of Mammary Gland Biology and Neoplasia
Published
2024-11-08
DOI
https://doi.org/10.1007/s10911-024-09571-3
Citations
4
Primary Topic
Cancer Risks and Factors
Type
article
Field-Weighted Citation Impact
1.13

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Gestational breast cancer: distinctive molecular and clinico-epidemiological features

Sònia Servitja, Federico Rojo, A. Rodriguez-Lescure, Begoña Bermejo et al.
4 citations
Journal of Mammary Gland Biology and Neoplasia
Cancer Risks and Factors
1.13
article

Gestational breast cancer: distinctive molecular and clinico-epidemiological features

Sònia Servitja, Federico Rojo, A. Rodriguez-Lescure, Begoña Bermejo, A. Guerrero-Zotano, Carmen Herrero, Marina Pollán, Pablo Mínguez, Emilio Alba, Jesús Herránz, Silvia Guil‐Luna, Juan de la Haba-Rodríguez, Cristina Hernándo, Natacha Martin, José Alejandro Pérez Fidalgo, Rosalía Caballero, Abraham Hernández-Blanquisett, A. Prat, María Teresa Martínez, Miguel Martín, S. Blanch, C Morales, Joaquín Gavilá, Regina Peña-Enríquez
article en
4 citations

Abstract

Gestational breast cancer (GBC), defined as breast cancer (BC) diagnosed during pregnancy or the first-year post-partum, accounts for 6-15% of BC cases in women aged 20-44 years. GBC has worse prognosis than non-GBC, but reasons behind are not clear. The GEICAM/2012-03 Study (Molecular Characterization of Gestational Breast Cancer) is a multicenter prospective/retrospective observational registry of patients diagnosed with GBC. From November 2014 to June 2015 seventy patients diagnosed with GBC were included in the study, 30 diagnosed during pregnancy and 40 after delivery. Our current study was aimed to explore differences in epidemiological, clinico-pathological and gene expression features of GBC tumors, from the GEICAM/2012-03 Study, compared to non-GBC tumors from patients of similar age (< 43 years) from six different GEICAM studies, used as non- GBC control population. As per the main objective, the study found multiple differences showing GBC tumors as a different biological entity. GBC showed a more aggressive biology, with higher Ki67 levels, higher incidence of breast and/or ovarian cancer family history, and germline deleterious BRCA1/2 mutations, and are enriched in basal-like intrinsic subtype. GBC patients showed a lower number of tumor infiltrating lymphocytes, while specific genetic signatures highlight differences in GBC´s distinctive transcriptome. Our study shows that GBC is potentially a clinically and molecularly different entity, with specific epidemiological, clinical, and histological features, as well as a distinctive altered immune state and genetic signature. Nevertheless, further studies are needed to better understand the biology of GBC and to identify new targets against which develop new, more effective, targeted therapies.

Journal of Mammary Gland Biology and NeoplasiaVol. 29(1)
Instituto de Salud Carlos III (ES), Hospital General Universitario Gregorio Marañón (ES), Instituto Maimónides de Investigación Biomédica de Córdoba (ES), Hospital Clínico Universitario de Valencia (ES), Consorcio Hospitalario Provincial de Castellón (ES), Fundación Instituto Valenciano de Oncología (ES), Centro Nacional de Epidemiología (ES), Centre for Biomedical Network Research on Rare Diseases (ES), Hospital Clínic de Barcelona (ES), Hospital General Universitario de Elche (ES), Hospital Universitario Reina Sofía (ES), Hospital Universitario Fundación Jiménez Díaz (ES), Hospital Del Mar (ES), CIBBIM-Nanomedicine (ES), Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (ES), Hospital Clínico Universitario Virgen de la Victoria (ES), INCLIVA Health Research Institute (ES), Centro de Investigación Biomédica en Red de Cáncer (ES), GEICAM – Spanish Breast Cancer Group (ES), Medical Research Network (US), Instituto de Investigación Biomédica de Málaga (ES), Vall d'Hebron Institute of Oncology (ES), University of Córdoba (ES), Universidad Autónoma de Madrid (ES)
Banco Bilbao Vizcaya Argentaria, Universidad de Córdoba, Instituto de Salud Carlos III, European Regional Development Fund
Good health and well-being
Openalex Percentile: Top 18%
Cancer Risks and Factors
1.13
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.